Last edited by Fenrigami
Saturday, July 18, 2020 | History

4 edition of Antiplatelet therapy found in the catalog.

Antiplatelet therapy

twenty years" experience : proceedings of a European conference, Florence, 26-28 March 1987

  • 334 Want to read
  • 8 Currently reading

Published by Excerpta Medica, Sole distributors for the USA and Canada, Elsevier Science Pub. Co. in Amsterdam, Princeton, New York, NY, USA .
Written in English

    Subjects:
  • Blood platelet disorders -- Chemotherapy -- Congresses.,
  • Blood platelets -- Aggregation -- Congresses.,
  • Fibrinolytic agents -- Congresses.,
  • Blood Platelets -- drug effects -- congresses.,
  • Platelet Aggregation -- drug effects -- congresses.

  • Edition Notes

    Includes bibliographies and indexes.

    Statementeditors, G.V.R. Born, G.G. Neri Serneri.
    SeriesCurrent clinical practice series ;, 44
    ContributionsBorn, Gustav V. R., Neri Serneri, G. G.
    Classifications
    LC ClassificationsRC647.B5 A58 1987
    The Physical Object
    Paginationx, 281 p. :
    Number of Pages281
    ID Numbers
    Open LibraryOL2400191M
    ISBN 100444904999
    LC Control Number87030298

      Antiplatelet Therapy in Cardiovascular Disease [Waksman, Ron, Gurbel, Paul A., Gaglia Jr., Michael A.] on *FREE* shipping on qualifying offers. Antiplatelet Therapy in Cardiovascular Disease.   The following are key points to remember about the updated guideline on duration of dual antiplatelet therapy (DAPT) in patients with coronary artery disease (CAD): The scope of this focused update is limited to addressing recommendations on duration of DAPT (aspirin plus a P2Y 12 inhibitor) in patients with coronary artery disease (CAD).

    Antiplatelet therapy is the cornerstone of treatment of ischemic cardiovascular disease and over the last few years spectacular advancements in this field have been recorded. This is the first comprehensive handbook entirely dedicated to all the aspects of antiplatelet therapy. The book is divided into three main sections, pathophysiology.   Dual antiplatelet therapy has also significantly reduced major cardiac events in patients with ACS. In these cases, platelet function testing helps determine drug efficacy and/or sensitivity, patients’ compliance with medication regimens, and optimal timing of urgent surgery after oral antiplatelet therapy ends (1).

    As the prevalence of cardiovascular disease (CVD) escalates worldwide, so does the use of antiplatelet medications in its management.[1] These agents are used to decrease major adverse events due to acute coronary syndromes, peripheral vascular disease, and stroke.[2] Despite a variety of pharmacologic actions, all antiplatelet drugs inhibit platelet activation and . Antiplatelet therapy is indicated in patients with PAD to reduce the risk of major cardiovascular events. However, remains an open issue why PAD represents an atherosclerotic clinical model where aspirin, differently from coronary heart disease, is less effective in .


Share this book
You might also like
John McClellan

John McClellan

century of spiritual service

century of spiritual service

History of St. Paul, Alberta, 1909-1959.

History of St. Paul, Alberta, 1909-1959.

Fish Creek Mountains Tuff and volcanic center, Lander County, Nevada

Fish Creek Mountains Tuff and volcanic center, Lander County, Nevada

Tralee back roads bike map

Tralee back roads bike map

growing plant.

growing plant.

Case studies in auditing procedure.

Case studies in auditing procedure.

wages of farm and factory laborers 1914-1944.

wages of farm and factory laborers 1914-1944.

Little Red Riding Hood

Little Red Riding Hood

Application of surface and bulk modified electrodes in electroanalytical chemistry

Application of surface and bulk modified electrodes in electroanalytical chemistry

Antiplatelet therapy Download PDF EPUB FB2

If the patient on antiplatelet therapy develops atrial fibrillation, the choice of oral anticoagulant therapy to be a part of the triple therapy is based on the same considerations as when the individual is not on antiplatelets ie dependent on the CHADS 2-VASC and HAS BLED scores. 41 If the bleeding risk is high, warfarin with a target INR of 2 Cited by:   This book in the new American Heart Association Clinical Series, explores and explains state-of-the-art use of antiplatelet agents and draws on the expertise of global leaders Antiplatelet therapy book antiplatelet therapy.

Skillfully organized for fast reference, the book is divided into five parts: Concepts in Platelet Physiology, Function, and MeasurementCited by: 1. This book in the new American Heart Association Clinical Series, explores and explains state-of-the-art use of antiplatelet agents and draws on the expertise of global leaders in antiplatelet therapy.

Skillfully organized for fast reference, the book is divided into five parts: Concepts in Platelet Physiology, Function, and MeasurementPrice: $ Edited by a team of the world’s leading interventional cardiologists and educators, this new book is created with an eye to giving the reader a solid, practical, and clinically focused understanding of this important class of drugs, from basic science to a clear-headed discussion of complex topics such as combination therapies, drug-to-drug interactions, and resistance to antiplatelet agents.

Description Dual Antiplatelet Therapy for Coronary and Peripheral Arterial Disease Antiplatelet therapy book a complete reference containing updated information on the advantages and disadvantages of dual antiplatelet therapy, its duration, composition and anticipated Edition: 1.

This book in the new American Heart Association Clinical Series, explores and explains state-of-the-art use of antiplatelet agents and draws on the expertise of global leaders in antiplatelet therapy.

Skillfully organized for fast reference, the book is divided into five parts. Antiplatelet medications divide into oral and parenteral agents. Oral agents subdivide further based on the mechanism of action. Aspirin is the first antiplatelet medication and is a cyclooxygenase inhibitor.

Others oral antiplatelet include clopidogrel, ticagrelor, and prasugrel, pentoxifylline, cilostazol, and dipyridamole. Glycoprotein IIb/IIIa inhibitors such as tirofiban.

This title will be presented as highly practical information pn pharmaceutical antiplatelet and anticoagulation therapy, written in a quick-access, no-nonsense format.

The emphasis will be on a just-the-facts clinical approach, heavy on tabular material, light on dense prose. Platelets -winner of a Highly Commended BMA Medical Book Award for Internal Medicine - is the definitive current source of state-of-the-art knowledge about platelets and covers the entire field of platelet biology, pathophysiology, and clinical ly there has been a rapid expansion of knowledge in both basic biology and the clinical approach to platelet-related.

is a rapid access, point-of-care medical reference for primary care and emergency clinicians. Started inthis collection now contains interlinked topic pages divided into a tree of 31 specialty books and chapters. In patients without an indication for anticoagulation therapy, aspirin or clopidogrel monotherapy is recommended in the periprocedural period.

Then, for the first months, either single or dual antiplatelet therapy is recommended, based on bleeding risk. After the initial months, single antiplatelet therapy is recommended long-term.

By agreement with the publisher, this book is accessible by the search feature, but cannot be browsed. Long-term antiplatelet therapy in PVD Marco Roffi and Guido Schnyder. PVD is a marker of generalized advanced atherosclerosis. “This book is designed as an accessible, up-to date reference for clinicians using antiplatelet and anticoagulation : $ The result is a unique book which is not only comprehensive but also clear and useful for the busy medical practitioner.

Keywords Anticoagulation Therapy Antiplatelet Therapy Aspirin Cardiology Warfarin prasugrel synthetic pentasaccharides unfractionated heparin. uous dual antiplatelet therapy, the combined rate of perioperative MI and mortality is the same as in stable coronary artery disease (1 to 6 percent, depending on the type of.

The Antiplatelet Trialists' Collaboration reported a 25% reduction in the risk of recurrent infarction, stroke, or vascular death in patients who received prolonged antiplatelet therapy (36 fewer events for every patients treated).

36 No antiplatelet therapy has proved superior to aspirin, and daily doses of aspirin between 75 and mg. Antiplatelet therapy is of proven benefit in coronary artery disease and a number of other clinical settings. This article reviews platelet function, molecular targets of antiplatelet agents, and clinical indications for antiplatelet therapy before focusing on a frequent question to hematologists about the 2 most commonly used antiplatelet therapies: Could the patient be.

Antiplatelet Therapy in Clinical Practice attempts to introduce this revolution to physicians practicing primarily in the field of cardiovascular medicine. The list of contributors illustrates that many specialists in this discipline are now also platelet by: 3.

What is antiplatelet therapy. Antiplatelets are a group of medicines that stop blood cells (called platelets) from sticking together and forming a blood clot. Whenever there is an injury in your body, platelets are sent to the site of the injury, where they clump together to form a blood clot.

This stops the bleeding in your body. The effect of platelet transfusion on functional independence and mortality after antiplatelet therapy associated spontaneous intracerebral hemorrhage: A systematic review and meta-analysis Author links open overlay panel Nicholas A.

Morris a g Nikhil Patel b Samuel M. Galvagno Jr c g Emilie Ludeman d Gary T. Schwartzbauer e g Ali Pourmand h. Antiplatelet therapy and treatment for other co-morbidities should be optimized.

The relative risks of a thromboembolic event and of bleeding should be weighed. Postoperative restarting of antiplatelet therapy depends on the individual patient's cardiovascular risk profile, the bleeding risks associated with the particular operation, and the.Duration: 3 months of dual Antiplatelet Therapy (DAPT) Gastrointestinal Bleeding event AND Stable Ischemic Heart Disease after Drug-eluting Stent; Duration: 6 months of dual Antiplatelet Therapy (DAPT) Standard duration of DAPT for Stable Ischemic Heart Disease after Drug-eluting Stent (as of ) Duration: 12 months of dual Antiplatelet.Stroke is a leading cause of mortality and disability worldwide.

1 Initial manifestations of acute cerebral ischemia, such as ischemic stroke and transient ischemic attack (TIA), are often followed by recurrent vascular events, including recurrent stroke.

2 To reduce this burden, antiplatelet therapy is a key component of the management of noncardioembolic ischemic stroke and TIA. .